Taigen Biopharmaceuticals Holdings Ltd (TWO:4157) — Market Cap & Net Worth
Market Cap & Net Worth: Taigen Biopharmaceuticals Holdings Ltd (4157)
Taigen Biopharmaceuticals Holdings Ltd (TWO:4157) has a market capitalization of $224.27 Million (NT$7.12 Billion) as of May 4, 2026. Listed on the TWO stock exchange, this Taiwan-based company holds position #16101 globally and #751 in its home market, demonstrating a -4.31% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Taigen Biopharmaceuticals Holdings Ltd's stock price NT$10.00 by its total outstanding shares 711833100 (711.83 Million). Analyse cash flow conversion of Taigen Biopharmaceuticals Holdings Ltd to see how efficiently the company converts income to cash.
Taigen Biopharmaceuticals Holdings Ltd Market Cap History: 2015 to 2026
Taigen Biopharmaceuticals Holdings Ltd's market capitalization history from 2015 to 2026. Data shows change from $758.05 Million to $224.27 Million (-9.47% CAGR).
Taigen Biopharmaceuticals Holdings Ltd Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Taigen Biopharmaceuticals Holdings Ltd's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
1.70x
Taigen Biopharmaceuticals Holdings Ltd's market cap is 1.70 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2015 | $758.05 Million | $78.00 Million | -$412.99 Million | 9.72x | N/A |
| 2016 | $610.00 Million | $146.02 Million | -$250.03 Million | 4.18x | N/A |
| 2017 | $486.66 Million | $553.21 Million | $746.38 Million | 0.88x | 0.65x |
| 2018 | $381.25 Million | $29.62 Million | -$343.21 Million | 12.87x | N/A |
| 2019 | $412.65 Million | $20.31 Million | -$295.69 Million | 20.31x | N/A |
| 2020 | $512.45 Million | $23.42 Million | -$404.82 Million | 21.88x | N/A |
| 2021 | $345.37 Million | $1.29 Billion | $775.62 Million | 0.27x | 0.45x |
| 2022 | $359.95 Million | $36.23 Million | -$237.16 Million | 9.94x | N/A |
| 2023 | $340.89 Million | $123.13 Million | $136.73 Million | 2.77x | 2.49x |
| 2024 | $256.79 Million | $150.65 Million | -$38.58 Million | 1.70x | N/A |
Competitor Companies of 4157 by Market Capitalization
Companies near Taigen Biopharmaceuticals Holdings Ltd in the global market cap rankings as of May 4, 2026.
Key companies related to Taigen Biopharmaceuticals Holdings Ltd by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #223 globally with a market cap of $107.56 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #367 globally with a market cap of $72.88 Billion USD.
- UCB SA (BR:UCB): Ranked #517 globally with a market cap of $51.45 Billion USD ( €44.01 Billion EUR).
- argenx NV ADR (NASDAQ:ARGX): Ranked #568 globally with a market cap of $45.97 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #223 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $107.56 Billion | $423.92 |
| #367 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $72.88 Billion | $701.42 |
| #517 | UCB SA | BR:UCB | $51.45 Billion | €231.20 |
| #568 | argenx NV ADR | NASDAQ:ARGX | $45.97 Billion | $787.95 |
Taigen Biopharmaceuticals Holdings Ltd Historical Marketcap From 2015 to 2026
Between 2015 and today, Taigen Biopharmaceuticals Holdings Ltd's market cap moved from $758.05 Million to $ 224.27 Million, with a yearly change of -9.47%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | NT$224.27 Million | -25.37% |
| 2025 | NT$300.52 Million | +17.03% |
| 2024 | NT$256.79 Million | -24.67% |
| 2023 | NT$340.89 Million | -5.30% |
| 2022 | NT$359.95 Million | +4.22% |
| 2021 | NT$345.37 Million | -32.60% |
| 2020 | NT$512.45 Million | +24.18% |
| 2019 | NT$412.65 Million | +8.24% |
| 2018 | NT$381.25 Million | -21.66% |
| 2017 | NT$486.66 Million | -20.22% |
| 2016 | NT$610.00 Million | -19.53% |
| 2015 | NT$758.05 Million | -- |
End of Day Market Cap According to Different Sources
On May 4th, 2026 the market cap of Taigen Biopharmaceuticals Holdings Ltd was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $224.27 Million USD |
| MoneyControl | $224.27 Million USD |
| MarketWatch | $224.27 Million USD |
| marketcap.company | $224.27 Million USD |
| Reuters | $224.27 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Taigen Biopharmaceuticals Holdings Ltd
TaiGen Biopharmaceuticals Holdings Limited, a pharmaceutical company, develops novel therapeutics for transformative diseases worldwide. The company develops Taigexyn (Nemonoxacin), a non-fluorinated quinolone antibiotic for the treatment of bacterial infections. Its product pipeline comprises Taigexyn, which is in phase II clinical trial for the treatment of community-acquired pneumonia/diabetic… Read more